Download PDF
Am J Perinatol 2011; 28(6): 449-460
DOI: 10.1055/s-0030-1270111
© Thieme Medical Publishers

Oxytocin Antagonists for the Management of Preterm Birth: A Review

Ihab M. Usta1 , Ali Khalil1 , Anwar H. Nassar1
  • 1Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Beirut, Lebanon
Further Information

Publication History

Publication Date:
17 December 2010 (online)

Also available at
    Permissions and Reprints

ABSTRACT

Preterm birth, the leading cause of neonatal morbidity and mortality, is estimated at incidence of 12.7% of all births, which has not decreased over the last four decades despite intensive antenatal care programs aimed at high-risk groups, the widespread use of tocolytics, and a series of other preventive and therapeutic interventions. Oxytocin antagonists, namely atosiban, represent an appealing choice that seems to be effective with apparently fewer side effects than the traditional tocolytics. This article reviews the available literature on the pharmacokinetics, mode of administration, and clinical utility of oxytocin antagonists for acute and maintenance tocolysis with special emphasis on its safety profile.

KEYWORDS

Oxytocin antagonists - tocolysis - preterm labor - adverse effects - dose

REFERENCES

  • 1 Hamilton B E, Martin J A, Ventura S J. Births: preliminary data for 2007.  Natl Vital Stat Rep. 2009;  57 1-23
    PubMedGoogle Scholar
  • 2 Copper R L, Goldenberg R L, Creasy R K et al.. A multicenter study of preterm birth weight and gestational age-specific neonatal mortality.  Am J Obstet Gynecol. 1993;  168 (1 Pt 1) 78-84
    CrossrefPubMedGoogle Scholar
  • 3 Morrison J C. Preterm birth: a puzzle worth solving.  Obstet Gynecol. 1990;  76 (1 Suppl) 5S-12S
    PubMedGoogle Scholar
  • 4 Akerlund M, Carlsson A M, Melin P, Trojnar J. The effect on the human uterus of two newly developed competitive inhibitors of oxytocin and vasopressin.  Acta Obstet Gynecol Scand. 1985;  64 499-504
    CrossrefPubMedGoogle Scholar
  • 5 Engstrøm T, Bratholm P, Vilhardt H, Christensen N J. Effect of oxytocin receptor and beta2-adrenoceptor blockade on myometrial oxytocin receptors in parturient rats.  Biol Reprod. 1999;  60 322-329
    CrossrefPubMedGoogle Scholar
  • 6 Goodwin T M, Millar L, North L, Abrams L S, Weglein R C, Holland M L. The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions.  Am J Obstet Gynecol. 1995;  173 (3 Pt 1) 913-917
    CrossrefPubMedGoogle Scholar
  • 7 Lundin S, Broeders A, Melin P. Pharmacokinetic properties of the tocolytic agent [Mpa1, D-Tyr(Et)2, Thr4, Orn8]-oxytocin (antocin) in healthy volunteers.  Clin Endocrinol (Oxf). 1993;  39 369-374
    CrossrefPubMedGoogle Scholar
  • 8 Valenzuela G J, Craig J, Bernhardt M D, Holland M L. Placental passage of the oxytocin antagonist atosiban.  Am J Obstet Gynecol. 1995;  172 (4 Pt 1) 1304-1306
    CrossrefPubMedGoogle Scholar
  • 9 Rasmussen B B, Larsen L S, Senderovitz T. Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers.  BJOG. 2005;  112 1492-1499
    PubMedGoogle Scholar
  • 10 eMC. Tractocile 7.5 mg/ml solution for injection. Available at: http://www.medicines.org.uk/EMC/medicine/4297/SPC/Tractocile+7.5+mg+ml+Solution+for+Injection/ Accessed June 24, 2010
    Google Scholar
  • 11 eMC. Tractocile 7.5 mg/ml concentrate for solution for infusion. Available at: http://www.medicines.org.uk/EMC/medicine/4305/SPC/Tractocile+7.5+mg+ml+Concentrate+for+Solution+for+Infusion/ Accessed June 24, 2010
    Google Scholar
  • 12 UKMi. New medicines on the market. Available at: http://www.ukmi.nhs.uk/NewMaterial/html/docs/atosiban.pdf Accessed June 24, 2010
    Google Scholar
  • 13 Kashanian M, Akbarian A R, Soltanzadeh M. Atosiban and nifedipin for the treatment of preterm labor.  Int J Gynaecol Obstet. 2005;  91 10-14
    CrossrefPubMedGoogle Scholar
  • 14 Goodwin T M, Paul R, Silver H et al.. The effect of the oxytocin antagonist atosiban on preterm uterine activity in the human.  Am J Obstet Gynecol. 1994;  170 474-478
    PubMedGoogle Scholar
  • 15 Goodwin T M, Valenzuela G J, Silver H, Creasy G. Atosiban Study Group . Dose ranging study of the oxytocin antagonist atosiban in the treatment of preterm labor.  Obstet Gynecol. 1996;  88 331-336
    CrossrefPubMedGoogle Scholar
  • 16 Thornton J G. The quality of randomised trials of tocolysis.  BJOG. 2006;  113 (Suppl 3) 93-95
    PubMedGoogle Scholar
  • 17 Romero R, Sibai B M, Sanchez-Ramos L et al.. An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue.  Am J Obstet Gynecol. 2000;  182 1173-1183
    CrossrefPubMedGoogle Scholar
  • 18 Romero R, Sirtori M, Oyarzun E et al.. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes.  Am J Obstet Gynecol. 1989;  161 817-824
    CrossrefPubMedGoogle Scholar
  • 19 Moutquin J M, Sherman D, Cohen H et al.. Double-blind, randomized, controlled trial of atosiban and ritodrine in the treatment of preterm labor: a multicenter effectiveness and safety study.  Am J Obstet Gynecol. 2000;  182 1191-1199
    CrossrefPubMedGoogle Scholar
  • 20 French/Australian Atosiban Investigators Group . Treatment of preterm labor with the oxytocin antagonist atosiban: a double-blind, randomized, controlled comparison with salbutamol.  Eur J Obstet Gynecol Reprod Biol. 2001;  98 177-185
    CrossrefPubMedGoogle Scholar
  • 21 European Atosiban Study Group . The oxytocin antagonist atosiban versus the beta-agonist terbutaline in the treatment of preterm labor. A randomized, double-blind, controlled study.  Acta Obstet Gynecol Scand. 2001;  80 413-422
    PubMedGoogle Scholar
  • 22 Worldwide Atosiban versus Beta-agonists Study Group . Effectiveness and safety of the oxytocin antagonist atosiban versus beta-adrenergic agonists in the treatment of preterm labour.  BJOG. 2001;  108 133-142
    CrossrefPubMedGoogle Scholar
  • 23 Papatsonis D, Flenady V, Cole S, Liley H. Oxytocin receptor antagonists for inhibiting preterm labour.  Cochrane Database Syst Rev. 2005;  (3) CD004452
    PubMedGoogle Scholar
  • 24 Al-Omari W R, Al-Shammaa H B, Al-Tikriti E M, Ahmed K W. Atosiban and nifedipine in acute tocolysis: a comparative study.  Eur J Obstet Gynecol Reprod Biol. 2006;  128 129-134
    CrossrefPubMedGoogle Scholar
  • 25 Coomarasamy A, Knox E M, Gee H, Song F, Khan K S. Effectiveness of nifedipine versus atosiban for tocolysis in preterm labour: a meta-analysis with an indirect comparison of randomised trials.  BJOG. 2003;  110 1045-1049
    PubMedGoogle Scholar
  • 26 Kim A, Shim J Y. Emerging tocolytics for maintenance therapy of preterm labour: oxytocin antagonists and calcium channel blockers.  BJOG. 2006;  113 (Suppl 3) 113-115
    PubMedGoogle Scholar
  • 27 Thornton J G. Maintenance tocolysis.  BJOG. 2005;  112 (Suppl 1) 118-121
    PubMedGoogle Scholar
  • 28 Norwitz E R, Bahtiyar M O, Sibai B M. Defining standards of care in maternal-fetal medicine.  Am J Obstet Gynecol. 2004;  191 1491-1496
    CrossrefPubMedGoogle Scholar
  • 29 Valenzuela G J, Sanchez-Ramos L, Romero R et al.. Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group.  Am J Obstet Gynecol. 2000;  182 1184-1190
    CrossrefPubMedGoogle Scholar
  • 30 Papatsonis D, Flenady V, Liley H. Maintenance therapy with oxytocin antagonists for inhibiting preterm birth after threatened preterm labour.  Cochrane Database Syst Rev. 2009;  (1) CD005938
    PubMedGoogle Scholar
  • 31 Helmer H, Brunbauer M, Rohrmeister K. Exploring the role of Tractocile in everyday clinical practice.  BJOG. 2003;  110 (Suppl 20) 113-115
    PubMedGoogle Scholar
  • 32 Goodwin T M, Valenzuela G, Silver H, Hayashi R, Creasy G W, Lane R. Treatment of preterm labor with the oxytocin antagonist atosiban.  Am J Perinatol. 1996;  13 143-146
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Lurie S, Sadan O, Ben Aroya Z, Glezerman M. Atosiban treatment for uterine hyperactivity during active labor: a pilot study.  J Perinat Med. 2004;  32 137-139
    CrossrefPubMedGoogle Scholar
  • 34 Afschar P, Schöll W, Bader A, Bauer M, Winter R. A prospective randomised trial of atosiban versus hexoprenaline for acute tocolysis and intrauterine resuscitation.  BJOG. 2004;  111 316-318
    PubMedGoogle Scholar
  • 35 de Heus R, Mulder E J, Derks J B, Kurver P H, van Wolfswinkel L, Visser G H. A prospective randomized trial of acute tocolysis in term labour with atosiban or ritodrine.  Eur J Obstet Gynecol Reprod Biol. 2008;  139 139-145
    CrossrefPubMedGoogle Scholar
  • 36 Fuchs A R, Fuchs F, Husslein P, Soloff M S, Fernström M J. Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor.  Science. 1982;  215 1396-1398
    CrossrefPubMedGoogle Scholar
  • 37 Fuchs A R, Fuchs F, Husslein P, Soloff M S. Oxytocin receptors in the human uterus during pregnancy and parturition.  Am J Obstet Gynecol. 1984;  150 734-741
    PubMedGoogle Scholar
  • 38 Richter O N, Dorn C, van de Vondel P, Ulrich U, Schmolling J. Tocolysis with atosiban: experience in the management of premature labor before 24 weeks of pregnancy.  Arch Gynecol Obstet. 2005;  272 26-30
    CrossrefPubMedGoogle Scholar
  • 39 Husslein P, Quartarolo J P. Review of clinical experience with atosiban and the Tractocile Efficacy Assessment Survey in Europe (TREASURE) study protocol.  Int J Clin Pract. 2003;  57 121-127
    PubMedGoogle Scholar
  • 40 Husslein P, Roura L C, Dudenhausen J TREASURE study group et al. Clinical practice evaluation of atosiban in preterm labour management in six European countries.  BJOG. 2006;  113 (Suppl 3) 105-110
    PubMedGoogle Scholar
  • 41 Treschan T A, Peters J. The vasopressin system: physiology and clinical strategies.  Anesthesiology. 2006;  105 599-612 quiz 639-640
    CrossrefPubMedGoogle Scholar
  • 42 Tsatsaris V, Carbonne B, Cabrol D. Atosiban for preterm labour.  Drugs. 2004;  64 375-382
    CrossrefPubMedGoogle Scholar
  • 43 Thornton S. Oxytocin receptor antagonists for inhibiting preterm labour. Available at: http://www.cochranefeedback.com/cf/cda/citation.do?id=9535#9535 Accessed June 24, 2010
    Google Scholar
  • 44 Food and Drug Administration .Antocin, (atosiban injection) for use in the management of preterm labor. Gaithersburg, MD: Centre for Drug Evaluation and Research, Advisory Committee for Reproductive Health Drugs; April 20, 1998. Issue-NDA 20–797 83-85
    Google Scholar
  • 45 Food and Drug Administration .Antocin, (atosiban injection) for use in the management of preterm labor. Gaithersburg, MD: Centre for Drug Evaluation and Research, Advisory Committee for Reproductive Health Drugs; April 20, 1998. Issue-NDA 20–797 24
    Google Scholar
  • 46 Papatsonis D N, Kok J H, van Geijn H P, Bleker O P, Adèr H J, Dekker G A. Neonatal effects of nifedipine and ritodrine for preterm labor.  Obstet Gynecol. 2000;  95 477-481
    CrossrefPubMedGoogle Scholar
  • 47 Papatsonis D N, Van Geijn H P, Adèr H J, Lange F M, Bleker O P, Dekker G A. Nifedipine and ritodrine in the management of preterm labor: a randomized multicenter trial.  Obstet Gynecol. 1997;  90 230-234
    CrossrefPubMedGoogle Scholar
  • 48 Goodwin T MRH, Perry K, Menard M K et al.. A report on infant outcomes up to 24 months of age after the use of atosiban in the management of preterm labour. Abstract presented at: 46th ACOG Annual Meeting May 9–13, 1998. New Orleans, LA;
    Google Scholar
  • 49 Akerlund M, Bossmar T, Brouard R et al.. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.  Br J Obstet Gynaecol. 1999;  106 1047-1053
    PubMedGoogle Scholar
  • 50 Pierzynski P, Lemancewicz A, Reinheimer T, Akerlund M, Laudanski T. Inhibitory effect of barusiban and atosiban on oxytocin-induced contractions of myometrium from preterm and term pregnant women.  J Soc Gynecol Investig. 2004;  11 384-387
    CrossrefPubMedGoogle Scholar
  • 51 Reinheimer T M, Bee W H, Resendez J C, Meyer J K, Haluska G J, Chellman G J. Barusiban, a new highly potent and long-acting oxytocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor.  J Clin Endocrinol Metab. 2005;  90 2275-2281
    CrossrefPubMedGoogle Scholar
  • 52 Thornton S, Goodwin T M, Greisen G, Hedegaard M, Arce J C. The effect of barusiban, a selective oxytocin antagonist, in threatened preterm labor at late gestational age: a randomized, double-blind, placebo-controlled trial.  Am J Obstet Gynecol. 2009;  200 627 e1-e10
    PubMedGoogle Scholar
  • 53 Reinheimer T M. Barusiban suppresses oxytocin-induced preterm labour in non-human primates.  BMC Pregnancy Childbirth. 2007;  7 (Suppl 1) S15
    CrossrefPubMedGoogle Scholar
  • 54 Wilson R J, Allen M J, Nandi M, Giles H, Thornton S. Spontaneous contractions of myometrium from humans, non-human primate and rodents are sensitive to selective oxytocin receptor antagonism in vitro.  BJOG. 2001;  108 960-966
    CrossrefPubMedGoogle Scholar
  • 55 Steinwall M, Bossmar T, Gaud C, Akerlund M. Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women.  Acta Obstet Gynecol Scand. 2004;  83 12-18
    PubMedGoogle Scholar
  • 56 Steinwall M, Bossmar T, Brouard R et al.. The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor.  Gynecol Endocrinol. 2005;  20 104-109
    CrossrefPubMedGoogle Scholar

Anwar H NassarM.D. 

American University of Beirut Medical Center

P.O. Box 113-6044/B36, Hamra Street, Beirut 110 32090, Lebanon

Email: an21@aub.edu.lb